Ask AI
ProCE Banner Activity

Phase III CheckMate 7FL: Biomarker Analysis of Addition of Nivolumab vs Placebo to Neoadjuvant CT and Adjuvant ET in High-Risk ER+/HER2- EBC

Conference Coverage
Slideset

In this exploratory analysis of the CheckMate 7FL trial, clinical efficacy with the addition of nivolumab vs placebo was greatest among patients with high-risk ER+/HER2- breast cancer whose tumors were PD-L1 positive, had stromal tumor-infiltrating lymphocytes, and expressed low levels of estrogen and/or progesterone receptors.

Released: December 08, 2023

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Merck Sharp & Dohme, LLC

Seagen Inc.